Kevin W. Sharer served as the CEO of Amgen, one of the leading biotechnology companies, from 2000 until 2012. He had a solid track record, helping the company grow its annual revenues from $3.3 billion in 1999 to $14.6 billion...

Kevin W. Sharer served as the CEO of Amgen, one of the leading biotechnology companies, from 2000 until 2012. He had a solid track record, helping the company grow its annual revenues from $3.3 billion in 1999 to $14.6 billion in 2009. Under his leadership, Amgen launched popular drugs like Epogen and Aranesp while also executing the largest acquisition in biotechnology at the time for the drug Enbrel. Sharer held various senior roles within Amgen before becoming CEO, including President and Chief Operating Officer. Not just a figurehead, his management style focused on real results, earning him a peak compensation of over $21 million in 2010, showing his alignment with the company's success. Even after his retirement, he maintained impressive stock holdings, owning 18,665 shares of Chevron, indicating he keeps a stake in big companies. Sharer enjoyed perks post-retirement too, like secretarial and tech support until 2017, reflecting his long years of service. He also served in the U.S. Navy, which shaped his leadership skills. With an educational background from UCLA and UC Santa Barbara, he combined technical know-how with practical business acumen.